Dextrin Or Derivative Patents (Class 514/58)
-
Publication number: 20130244979Abstract: 6-deoxy-6-thioether-amino acid cyclodextrin derivative is obtained by condensing an amino acid derivative with halogenated cyclodextrin in presence of alkali. The 6-deoxy-6-thioether-amino acid cyclodextrin derivative includes 6-deoxysulfinyl-6-thioether-amino acid cyclodextrin derivative and 6-deoxysulfonyl-6-thioether-amino acid cyclodextrin derivative. Compounds provided are for reversing neuromuscular relaxation in patients and animals induced by muscular relaxants. The compounds are able to rapidly reverse and antagonize muscular relaxation induced by muscular relaxants and can be administrated in preparing a drug having an antagonist effect on muscular relaxation. The compounds have a general formula (I).Type: ApplicationFiled: November 21, 2011Publication date: September 19, 2013Inventor: Youmao Qi
-
Patent number: 8518910Abstract: The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a ?-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.Type: GrantFiled: January 17, 2012Date of Patent: August 27, 2013Assignee: Curis, Inc.Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai, Rudi Bao
-
Patent number: 8512758Abstract: A powder composition, includes: (A) an oil-soluble antioxidant substance powder; (B) a water-soluble antioxidant substance powder; and (C) at least one of zinc, selenium, manganese and copper.Type: GrantFiled: September 3, 2008Date of Patent: August 20, 2013Assignee: FUJIFILM CorporationInventor: Fumitaka Ueda
-
Publication number: 20130209444Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.Type: ApplicationFiled: January 30, 2013Publication date: August 15, 2013Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Baxter International Inc., Baxter Healthcare S.A.
-
Patent number: 8507461Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.Type: GrantFiled: September 6, 2006Date of Patent: August 13, 2013Inventor: Abdalla Rifai
-
Publication number: 20130203700Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: February 15, 2013Publication date: August 8, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Publication number: 20130202601Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the afore-mentioned disorders.Type: ApplicationFiled: October 14, 2011Publication date: August 8, 2013Inventors: Alessia Fornoni, George William Burke, Sandra Merscher-Gomez
-
Publication number: 20130196947Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: UNIVERSITE DE LIEGEInventor: UNIVERSITE DE LIEGE
-
Publication number: 20130196906Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.Type: ApplicationFiled: January 29, 2013Publication date: August 1, 2013Applicant: CERULEAN PHARMA INC.Inventor: Cerulean Pharma Inc.
-
Publication number: 20130196946Abstract: Methods and compositions relating to CDP-taxane conjugates are described herein.Type: ApplicationFiled: January 14, 2013Publication date: August 1, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Publication number: 20130196945Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: January 11, 2013Publication date: August 1, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Publication number: 20130196948Abstract: Described herein are inventive compositions and methods relating to polymer conjugates and, in particular, to polymer conjugates having pendant side groups comprising ring moieties. In one aspect, embodiments are generally related to compositions that mimic naturally-occurring polyphenol compounds. The compositions comprise, in some embodiments, a polymer backbone having a plurality of hydroxyaromatic pendant side groups or derivatives thereof. For example, in some cases, a pendant side group may be a phenol or a substituted derivative thereof. In some cases, the pendant side group may be an oxidized hydroxyaromatic group, such as a quinone. In some embodiments, self-assembled structures comprising one or more of the polymer conjugates are provided. For example, the polymer conjugates may be combined with a complexing agent to form a particle. In some cases, a polymer conjugate may form a hydrogel.Type: ApplicationFiled: June 23, 2011Publication date: August 1, 2013Applicant: MASSACHUSETTS INSITUTE OF TECHNOLOGYInventors: Omar Fisher, Christopher G. Levins, Robert S. Langer, Daniel Griffith Anderson
-
Patent number: 8492538Abstract: Chiral salts comprising anionic cyclodextrin derivatives with particular types of non-metal cations are provided. The anionic CD derivative salts can serve as ionic liquids and can possess substantial advantages over currently commercially available ionic liquids particularly for use as chiral phase transfer catalyst, chiral reaction medium, chiral extraction medium, and/or as chiral additive to a chemical process. Methods of preparing the same are provided.Type: GrantFiled: June 2, 2010Date of Patent: July 23, 2013Inventor: Jose R. Matos
-
COMPOUND HAVING DETRUSOR MUSCLE-CONTRACTING ACTIVITY AND URETHRAL SPHINCTER MUSCLE-RELAXING ACTIVITY
Publication number: 20130184236Abstract: Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and/or ameliorating underactive bladder.Type: ApplicationFiled: March 4, 2013Publication date: July 18, 2013Applicant: ONO PHARMACEUTICAL CO., LTD.Inventor: ONO PHARMACEUTICAL CO., LTD. -
Publication number: 20130183369Abstract: Means, compositions, and uses for triggering exocytosis of lysosomes in living cells. During exocytosis, lysosomes travel to the plasma membrane of the cell and dump their contents outside of the cells, thus removing accumulations of harmful, reactive metabolic by-products, such as lipofuscin. Consequently, cells function better, thus improving their vitality and the vitality of people, animals, and cell cultures. Degenerative diseases can be prevented or reversed. Embodied methods include electrical pulses, sonic vibrations, mechanical pressure, and mixtures of substances, which may include drugs, proteins, antibodies, or liposomes, which can be combined, injected, or administered transdermally or orally. Other embodiments are described and shown.Type: ApplicationFiled: July 12, 2012Publication date: July 18, 2013Inventor: John Douglas Furber
-
Patent number: 8481511Abstract: A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056M?1-13051M?1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and/or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely dissolved; said solution is filtered in 0.2-04 ?m microporous membrane then ethanol is removed through reduced pressure to obtain the inclusion complex in a liquid form; or ethanol, followed by water is removed through reduced pressure, then dried to obtain the inclusion complex in a solid form.Type: GrantFiled: October 13, 2006Date of Patent: July 9, 2013Assignee: Hainan Hdeton Science and Technology Co., Ltd.Inventors: Yong Ren, Jianfeng Gao, Shuqin Yu, Ling Wu
-
Publication number: 20130172291Abstract: The present invention discloses certain polyene cyclodextrin acetals and hemiacetals that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof.Type: ApplicationFiled: February 14, 2013Publication date: July 4, 2013Applicant: ISLAND KINETICS INC.Inventor: ISLAND KINETICS INC.
-
Patent number: 8476248Abstract: The present invention provides products having resveratrol with high water solubility and nutraceutical and/or phytotherapic compositions having said substances. The processes for obtaining them include the solubility increase of the polyphenol corresponding to a resveratrol compound, preferably trans-resveratrol in water, by its complexation with cyclodextrin under specific conditions that favor thermodynamic equilibrium. The products of the invention present high solubility and purity in aqueous medium, being, therefore, useful to prepare nutraceutical compositions (pharmaceutical and/or alimentary) with antioxidant, anti-inflammatory, antiviral, antidiabetics, cardioprotective, neuroprotective, chemoprotective activities; besides protecting against infections and ischemia, reducing obesity, and preventing aging.Type: GrantFiled: July 23, 2008Date of Patent: July 2, 2013Assignees: Uniao Brasileira de Educacao e Assistencia—Mantenedora da PUCRS, Eurofarma Laboratorios Ltda.Inventor: Andre Arigony Souto
-
Publication number: 20130164282Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.Type: ApplicationFiled: February 15, 2013Publication date: June 27, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Publication number: 20130165405Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: February 15, 2013Publication date: June 27, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Publication number: 20130157975Abstract: An object of the present invention is to provide an agent for suppressing elevation of blood alcohol concentration and a method for suppressing elevation of blood alcohol concentration, the agent and the method enabling prevention of an intoxication state upon drinking and further prevention of hepatic dysfunctions due to drinking such as fatty liver. Provided are an agent for suppressing elevation of blood alcohol concentration, comprising a dextrin as an active ingredient, and a method for suppressing elevation of blood alcohol concentration, comprising, when alcohol is ingested, ingesting 0.5 parts by mass or more of a digestible dextrin and/or an indigestible dextrin relative to 1 part by mass of the ingested alcohol.Type: ApplicationFiled: December 11, 2012Publication date: June 20, 2013Applicant: MATSUTANI CHEMICAL INDUSTRY CO., LTD.Inventor: MATSUTANI CHEMICAL INDUSTRY CO., LTD.
-
Publication number: 20130156857Abstract: A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed.Type: ApplicationFiled: February 15, 2013Publication date: June 20, 2013Applicant: TWI BIOTECHNOLOGY, INC.Inventor: TWI BIOTECHNOLOGY, INC.
-
Publication number: 20130156721Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: February 15, 2013Publication date: June 20, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Patent number: 8466278Abstract: This invention relates to novel ?-cyclodextrin polysulfate compounds comprising from one to three 2-carboxyethyl substituents, and at least two sulfates groups per glucopyranose unit, which are useful as active ingredients for the treatment and/or prophylaxis of degenerative joint diseases, osteoarthritis, articular rheumatism, arthrosis or degenerative arthritis, or for the treatment of heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair.Type: GrantFiled: September 22, 2009Date of Patent: June 18, 2013Assignee: Arcarios B.V.Inventors: Dirk Elewaut, August Lodewijk Verbruggen
-
Patent number: 8461133Abstract: The invention relates to a method for preparing a soluble inclusion complex comprising one or several active substances which are hardly soluble in an aqueous medium and are included in one or several host molecules, characterised in that it comprises the following succesive stages: (a) one or several active substances are brought into contact with one or several host molecules; (b) initiation of a molecular diffusion stage by bringing a dense pressurized fluid into contact with the mixture obtained in stage (a) in a static mode in the presence of one or several diffusing agents; (c) recovery of the active substance- host molecule molecular complex thus formed; (d) initiation of a stage wherein an interaction agent is added to and mixed with the active substance host molecule molecular complex; (e) recovery of the soluble inclusion compound thus formed. The invention also relates to the soluble inclusion compound which can be obtained by said method, particularly a piroxicam-cyclodextrin-arginine compound.Type: GrantFiled: March 29, 2005Date of Patent: June 11, 2013Assignee: Pierre Fabre MedicamentInventors: Bernard Freiss, Florence Marciaçq, Hubert Lochard
-
Publication number: 20130142791Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.Type: ApplicationFiled: February 4, 2013Publication date: June 6, 2013Applicant: OCULIS EHFInventors: Thorsteinn LOFTSSON, Einar STEFÁNSSON
-
Patent number: 8455464Abstract: A composition for the treatment of adhesions that are formed as a result of an inflammatory response comprising an aqueous formulation containing the polysaccharide dextrin in an effective amount. The invention also discloses a method of treating adhesions that are formed as a result of an inflammatory response.Type: GrantFiled: January 19, 2001Date of Patent: June 4, 2013Assignee: Innovata LimitedInventor: Susan Conroy
-
Publication number: 20130137657Abstract: Use of a compound of formula (I): wherein the symbol cyclodextrin? ]n represents a n-valent residue derived from a cyclodextrin compound by removing n of its hydroxyl groups; n is a number greater than 0 and represents the average number of substituents of formula per molecule of said compound; h is 0 or 1; R1 is a di-valent group selected from alkylene, hydroxy alkylene, halogeno alkylene, monocyclic aralkylene, cycloalkylene and phenylene; R2, R3 and R4 are each independently of one another a group selected from alkyl, cycloalkyl, aryl, aralkyl, and cycloheteryl; Xm? is a m-fold negatively charged anion; m is an integer being equal or greater than 1; and k is n/m in the preparation of an anti-infective medicament, as preservative and penetration enhancer.Type: ApplicationFiled: December 21, 2012Publication date: May 30, 2013Applicant: NOVARTIS AGInventor: NOVARTIS AG
-
Publication number: 20130129700Abstract: The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution.Type: ApplicationFiled: November 30, 2012Publication date: May 23, 2013Applicant: Cydex Pharmaceuticals, Inc.Inventor: Cydex Pharmaceuticals, Inc.
-
Publication number: 20130131013Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: January 11, 2013Publication date: May 23, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Publication number: 20130129665Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: January 11, 2013Publication date: May 23, 2013Applicant: CERULEAN PHARMA INC.Inventor: Cerulean Pharma Inc.
-
Patent number: 8445460Abstract: The invention relates to soluble, highly branched glucose polymers which are obtained by enzymatic treatment of starch, having a reducing sugars content of less than 3.5%, exhibiting a proportion of ?-1,6-glucosidic linkages of between 20% and 30%, a Mw, determined by light scattering, of between 20·103 and 30·103 daltons, and an osmolality of less than 25 mOsm/kg. The invention likewise relates to a method of obtaining these polymers and to their use in the pharmaceutical and food industries, more particularly in the field of enteral and parenteral nutrition, and in the field of peritoneal dialysis.Type: GrantFiled: February 15, 2007Date of Patent: May 21, 2013Assignee: Roquette FreresInventors: Laëtitia Deremaux, Carole Petitjean, Daniel Wills
-
Publication number: 20130123214Abstract: This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of delta tocopherol in combination with cyclodextrin to a patient in need thereof.Type: ApplicationFiled: July 19, 2011Publication date: May 16, 2013Applicant: The United States of America as Represented by the Secretary Department of HRInventors: Wei Zheng, Juan Jose Marugan, Ke Liu, Noel Terrence Southall, Christopher P. Austin
-
Patent number: 8440814Abstract: The invention relates to a compound corresponding to general formula (I) wherein n is a whole number from 1-6, m is a whole number equal to 5, 6 or 7, R1 is an OH group, all R1 s are identical, Z is an NHX group, X is a hydrogen atom, and R is a hydrogen atom or a bioidentification element, with the proviso that the compound wherein n=1, m=6, Z=NH2 and R1=OH is excluded.Type: GrantFiled: May 19, 2009Date of Patent: May 14, 2013Assignees: Centre National de la Recherche Scientifique, Universite Joseph Fourier, Consejo Superior de Investigaciones Cientificas (CSIC), Universidad de SevillaInventors: Jacques Defaye, Carmen Ortiz-Mellet, Jose Manuel Garcia-Fernandez, Maria Gomez-Garcia, Kazimierz Chmurski, Jian-Xin Yu
-
Patent number: 8440227Abstract: A biological adhesive formulation comprising dextrin, at least one adhesiveness modifier agent, and at least one antibiotic is suitable for promoting healing of tissue in a patient, for example, to prevent anastomosis of a surgical wound in the digestive system of a patient, and for affixing prosthesis during a hernia operation in a patient and occluding a fistula within a patient.Type: GrantFiled: April 23, 2012Date of Patent: May 14, 2013Inventor: Jorge Cueto-Garcia
-
Patent number: 8435967Abstract: Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present disclosure is a process for making a water dispersible policosanol cyclodextrin complex for animal ingestion. This method includes preparing a policosanol cyclodextrin complex and administering said complex to an animal. The preferred animal is a human with the route of administration being oral ingestion. The form of the complex for ingestion can be a hard gelatin capsule, tablet or wafers, which may contain other ingredients, both active and inactive. The complex also can be further formulated with excipients suitable for soft gelatin capsules, such as, for example, vegetable oils, waxes, lecithin, and surfactants such as Tween-80.Type: GrantFiled: December 1, 2010Date of Patent: May 7, 2013Assignee: Bio-Actives LLCInventors: Doddabele L. Madhavi, Daniel I. Kagan
-
Patent number: 8435966Abstract: The invention is related to association products of xanthates and cyclodextrins, pharmaceutical formulations made therefrom, and medicaments containing these formulations for treating Alzheimer's, viral, tumor, cardiovascular, and autoimmune diseases such as rheumatism, multiple sclerosis, alopecia areata, lupus erythematosus, stroke, lung edema, or for use as radio-protectors. The association products contain a xanthate of general formula I whereby R1 represents a possibly substituted aryl or alkyl residue and R2 represents a metal atom, a possibly substituted alkyl, alkoxy, amino or ammonium group or halogen, and a cyclodextrin, whereby the cyclodextrin can be either a substituted or non-substituted alpha-, beta- or gamma-cyclodextrin. Furthermore, the invention is related to the use of the association products for chemical syntheses.Type: GrantFiled: March 13, 2007Date of Patent: May 7, 2013Assignee: Biosphings AGInventor: Eberhard Amtmann
-
Patent number: 8431549Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.Type: GrantFiled: May 25, 2010Date of Patent: April 30, 2013Assignee: Luitpold Pharmaceuticals, Inc.Inventors: Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
-
Patent number: 8426385Abstract: A pharmaceutical composition comprising cyclodextrin/paclitaxel inclusion, which consists of paclitaxel, cyclodextrin and a pharmaceutically acceptable excipient, wherein the mass ratio of the paclitaxel to cyclodextrin is 1:10-150, the said cyclodextrin is hydroxylpropyl-sulfobutyl-7-?-cyclodextrin, or sulfobutylether-7-?-cyclodextrin, or their mixture; the stability constant of the cyclodextrin/paclitaxel inclusion is Ka=5396M?1?1412M?1. The preparation method of the pharmaceutical composition is as follow: (a) A solution of cyclodextrin is added dropwise to a solution of paclitaxel in ethanol. (b) The resulting mixture is filtered through microporous membrane of 0.2-0.4 ?m after being dissolved. (c) Ethanol is removed under reduced pressure to give a liquid inclusion which has the ethanol level of less than 2%, or alternatively water is also removed under reduced pressure, the resulting product is dried giving a solid inclusion.Type: GrantFiled: October 13, 2006Date of Patent: April 23, 2013Assignee: Hainan Hdeton Science and Technology Co. Ltd.Inventors: Yong Ren, Jianfeng Gao, Shuqin Yu, Ling Wu
-
Patent number: 8420621Abstract: Disclosed are methods of producing a blunted postprandial glycemic response in an individual, and/or reducing postprandial insulin secretion, said methods comprising administering to the individual a nutritional or other product comprising gamma-cyclodextrin. Also disclosed are similar other methods directed toward the use of such products to provide weight and appetite control, to normalize blood glucose levels in individuals with impaired glucose tolerance, to minimize nighttime hypoglycemia in diabetic and non-diabetic patients, to prevent reactive hypoglycemia in susceptible non-diabetics, to normalize blood glucose levels in individuals with gestational diabetes or impaired glucose tolerance during gestation, and/or to provide a prolonged glycemic response during exercise.Type: GrantFiled: June 5, 2008Date of Patent: April 16, 2013Assignee: Abbott LaboratoriesInventors: Chron-Si Lai, JoMay Chow, Bryan W. Wolf
-
Publication number: 20130090371Abstract: The present invention generally relates to compositions and kits comprising a ?2-AR agonist and a modulator of a ?2-AR regulator gene, where the modulator of the ?2-AR regulator gene inhibits the internalization and/or degradation of the ?2-ad-renergic receptor (?2-AR). More specifically, the present invention relates to the use of an agonist of ?2-adrenergic receptor (?2-AR) and an agent which inhibits agonist induced ?2-adrenergic receptor (?2-AR) internalization and/or degradation in method for the treatment of a respiratory disorder in a subject.Type: ApplicationFiled: April 20, 2011Publication date: April 11, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventor: Quan Lu
-
Patent number: 8410077Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.Type: GrantFiled: November 5, 2009Date of Patent: April 2, 2013Assignee: CyDex Pharmaceuticals, Inc.Inventor: Vincent Antle
-
Patent number: 8404717Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.Type: GrantFiled: March 24, 2011Date of Patent: March 26, 2013Assignee: Celgene CorporationInventor: Jerome B. Zeldis
-
Patent number: 8404662Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: August 10, 2012Date of Patent: March 26, 2013Assignees: Cerulean Pharma Inc., Insert Therapeutics, Inc., Calando Pharmaceuticals, Inc.Inventors: Jianjun Cheng, Mark Davis, Kay T. Khin
-
Patent number: 8404716Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.Type: GrantFiled: May 11, 2010Date of Patent: March 26, 2013Assignee: Celgene CorporationInventor: Jerome B. Zeldis
-
Patent number: 8399431Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: July 19, 2012Date of Patent: March 19, 2013Assignees: Cerulean Pharma Inc., Insert Therapeutics, Inc., Calando Pharmaceuticals, Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Publication number: 20130059817Abstract: This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fibre together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia.Type: ApplicationFiled: May 13, 2011Publication date: March 7, 2013Applicant: INQPHARM SDN BHDInventors: Pee Win Chong, Thomas Hafner, Istvan Puskas
-
Publication number: 20130059816Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.Type: ApplicationFiled: October 24, 2012Publication date: March 7, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC
-
Patent number: 8389499Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: July 19, 2012Date of Patent: March 5, 2013Assignees: Cerulean Pharma Inc., Insert Therapeutics, Inc., Calando Pharmaceuticals, Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Patent number: 8383606Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.Type: GrantFiled: November 5, 2009Date of Patent: February 26, 2013Assignee: CyDex Pharmaceuticals, Inc.Inventor: Vincent Antle